Ensartinib
HCl is the salt form of Ensartinib, an orally available small molecule
inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase
(ALK) with potential antineoplastic activity. Upon oral administration,
X-396 binds to and inhibits ALK kinase, ALK fusion proteins and ALK
point mutation variants. Inhibition of ALK leads to the disruption of
ALK-mediated signaling and eventually inhibits tumor cell growth in
ALK-expressing tumor cells. ALK belongs to the insulin receptor
superfamily and plays an important role in nervous system development.
